Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2015 February;56(1) > The Journal of Cardiovascular Surgery 2015 February;56(1):11-8

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632


eTOC

 

  ASCENDING AORTIC LESIONS


The Journal of Cardiovascular Surgery 2015 February;56(1):11-8

language: English

Experiences with ascending aortic endografts using FDA IDE approved devices. What has been done, what lesions can be treated and what challenges remain

Muehle A., Chou D., Shah A., Khoynezhad A.

Division of Cardiothoracic Surgery, Cedars‑Sinai Heart Institute, Los Angeles, CA, USA


PDF  


Thoracic endovascular aortic repair (TEVAR) has become an attractive treatment option for thoracic aortic disease. New devices and advanced image-guided procedures are continuously expanding the indications. With improving device technology, diverse stent-graft availability, and imaging modalities, TEVAR has become safer and holds promising potential to expand treatment options, especially for ascending aorta and aortic arch pathology. This article focuses on current evolving endovascular solutions for thoracic ascending aortic diseases and starts with an overview of historical TEVAR landmarks, followed by indications for TEVAR, and concludes with present day challenges.

top of page

Publication History

Cite this article as

Corresponding author e-mail

akhoy@cshs.org